Exploring US High Growth Tech Stocks For Potential Portfolio Expansion

As the U.S. stock market navigates a landscape of fluctuating indices and economic indicators, investors are closely monitoring the Federal Reserve's interest rate decisions and major tech earnings reports, which have recently driven optimism despite intermittent setbacks. In this dynamic environment, identifying high growth tech stocks that align with strong corporate earnings and favorable economic data can be an effective strategy for those looking to expand their portfolios amidst evolving market conditions.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 70 stocks from our US High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

CuriosityStream (CURI)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: CuriosityStream Inc. is a media and entertainment company that offers factual content across various platforms, with a market cap of $269.50 million.

Operations: CuriosityStream generates revenue primarily from its Curiosity Stream segment, which brought in $54.22 million.

CuriosityStream, a burgeoning name in the tech-driven entertainment sector, is making significant strides with its innovative streaming service, Curiosity University. This platform has recently expanded into European markets through Amazon Prime Video Channels in Sweden and the UK, blending academic rigor with compelling storytelling to tap into a growing demand for knowledge-rich content. Impressively, CuriosityStream's earnings are projected to surge by 110.8% annually. Moreover, the company has been actively enhancing shareholder value through strategic shelf registration filings totaling $13.77 million and declaring special dividends reflecting robust improvements in cash flow and profitability—a testament to its financial health and forward-looking management strategies.

• Dive into the specifics of CuriosityStream here with our thorough health report.

• Assess CuriosityStream's past performance with our detailed historical performance reports.

Mereo BioPharma Group (MREO)

Simply Wall St Growth Rating: ★★★★★★

Overview: Mereo BioPharma Group plc is a biopharmaceutical company focused on developing and commercializing therapeutics for oncology and rare diseases across the UK, US, and internationally, with a market cap of $279.84 million.

Operations: Mereo BioPharma Group focuses on developing therapeutics for oncology and rare diseases, with operations spanning the UK, US, and international markets. The company's revenue streams are primarily derived from its biopharmaceutical products in these specialized fields.

Mereo BioPharma Group, amid a challenging landscape, is steering towards profitability with an anticipated revenue growth of 51.1% per year, significantly outpacing the US market's average of 9%. This growth trajectory is supported by promising developments in their clinical programs, notably the Phase 3 study of setrusumab for osteogenesis imperfecta. Despite a recent increase in net loss to $12.89 million from last year's $8.95 million, Mereo's strategic focus on rare genetic diseases positions it uniquely within the biotech sector. The company’s R&D commitment is underscored by its ongoing investment in innovative therapies that address unmet medical needs, setting a foundation for potential future success in a highly specialized market.

• Unlock comprehensive insights into our analysis of Mereo BioPharma Group stock in this health report.

• Understand Mereo BioPharma Group's track record by examining our Past report.

Vanda Pharmaceuticals (VNDA)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for high unmet medical needs globally, with a market cap of $276.99 million.

Operations: Vanda Pharmaceuticals focuses on developing and commercializing therapies for unmet medical needs, generating revenue primarily from its biotechnology segment, which contributed $201.35 million.

Vanda Pharmaceuticals, recently added to the Russell 2000 Defensive Index, is navigating a transformative phase with a projected annual revenue growth of 27.1%. This growth is bolstered by innovative clinical trials like the first-in-human study for VCA-894A targeting Charcot-Marie-Tooth disease, highlighting its strategic pivot towards specialized therapeutic areas. Despite a substantial net loss increase to $29.49 million in Q1 2025 from $4.15 million previously, Vanda's aggressive R&D investment reflects its commitment to addressing rare genetic disorders, potentially reshaping treatment paradigms and driving future profitability expected within three years.

• Click here and access our complete health analysis report to understand the dynamics of Vanda Pharmaceuticals.

• Evaluate Vanda Pharmaceuticals' historical performance by accessing our past performance report.

Next Steps

• Click here to access our complete index of 70 US High Growth Tech and AI Stocks.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com